KATHERINE BUCK: Open Payments
NPI 1659772986 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,565 in 67 payments from 19 companies in 2025. Trend: 2023 $10,098 · 2024 $1,921 · 2025 $1,565
Food & beverage: $1,365Education: $200
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $377 |
| Daiichi Sankyo Inc. | 9 | $266 |
| ABBVIE INC. | 8 | $214 |
| Merck Sharp & Dohme LLC | 5 | $103 |
| Eisai Inc. | 4 | $102 |
| Stemline Therapeutics Inc. | 5 | $89 |
| Astellas Pharma US Inc | 5 | $73 |
| Lilly USA, LLC | 4 | $59 |
| Novo Nordisk Inc | 2 | $44 |
| Genmab U.S., Inc. | 2 | $36 |
Products named: Enhertu, LYNPARZA, ELAHERE, KEYTRUDA, Lenvima, Orserdu, Veozah, VERZENIO.
Industry payments across OK — which companies pay providers there.
